Minerva Neurosciences Inc 's Cash & cash equivalent grew by 2.23 % in the Q3 2026 sequentially, while Current Liabilities decreased, this led to improvement in Minerva Neurosciences Inc 's Quick Ratio to 30.46, above Minerva Neurosciences Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 44 other companies have achieved higher Quick Ratio than Minerva Neurosciences Inc in third quarter 2026. While Quick Ratio total ranking in the third quarter 2026 has deteriorated compared to the prior quarter from 180 to 198.

Explain Quick Ratio?
How much Cash & cash equivalents NERV�s has?
What are NERV�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/NERV/financial-strength

https://api.csimarket.com/api/v1/companies/NERV/fundamentals

https://api.csimarket.com/api/v1/companies/NERV/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

NERV Quick Ratio	(Sep 30 2026) Q3	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3
Y / Y Current Liabilities Change	-5.48 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	526.25 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	30.46	Subscribe	Subscribe	Subscribe	Subscribe
NERV's Total Ranking	# 198	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-36.18 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	2.23 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio third quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 45
Healthcare Sector	# 64
Overall Market	# 198

Quick Ratio Statistics
High	Average	Low
35.93	12.69	0.05
(Dec 31 2025)		(Jun 30 2014)

Financial Statements
Minerva Neurosciences Inc 's Current Liabilities	$ 3 Millions	Visit NERV's Balance sheet
Minerva Neurosciences Inc 's Cash & cash equivalent	$ 77 Millions	Visit NERV's Balance sheet
Source of NERV's Sales		Visit NERV's Sales by Geography

Cumulative Minerva Neurosciences Inc 's Quick Ratio

NERV's Quick Ratio for the trailling 12 Months

NERV Quick Ratio	(Sep 30 2026) 12 Months	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	32.76 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	372.27 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	23.58	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 2950	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-1.09 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	26.08 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to NERV Financial Strength Comparisons >> Go to Compare NERV Quick Ratio to its Competitors

On the trailing twelve months basis NERV Cash & cash equivalent more than doubled by 526.25 % in Q3 2026 year on year, while Current Liabilities plummeted to $3 millions, this led to increase in in Minerva Neurosciences Inc 's Quick Ratio to 23.58, above NERV average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 405 other companies have achieved higher Quick Ratio than Minerva Neurosciences Inc . While Quick Ratio overall ranking has improved so far to 2950, from total ranking during the twelve months ending second quarter 2026 at 3070.

Explain Quick Ratio?
How much Cash & cash equivalents NERV�s has?
What are NERV�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 406
Healthcare Sector	# 801
Within the Market	# 2950

trailing twelve months Quick Ratio Statistics
High	Average	Low
20.55	12.69	5.66
(Jun 30 2023)		(Dec 31 2020)

Companies with similar Quick Ratio in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2026 MRQ Cash & cash equivalent	Sep 30 2026 MRQ Current Liabilities
Q32 Bio Inc	56.05	$ 289.587 Millions	$ 5.167 Millions
Rallybio Corporation	51.94	$ 90.693 Millions	$ 1.746 Millions
Enliven Therapeutics Inc	45.41	$ 884.351 Millions	$ 19.473 Millions
Tango Therapeutics Inc	38.85	$ 977.503 Millions	$ 25.164 Millions
Trevi Therapeutics Inc	38.05	$ 299.408 Millions	$ 7.869 Millions
Whitehawk Therapeutics Inc	32.48	$ 339.094 Millions	$ 10.441 Millions
Minerva Neurosciences Inc	30.46	$ 76.945 Millions	$ 2.526 Millions
Contineum Therapeutics Inc	30.45	$ 244.484 Millions	$ 8.028 Millions
Latigo Biotherapeutics, Inc.	28.73	$ 401.241 Millions	$ 13.964 Millions
Amylyx Pharmaceuticals Inc	26.44	$ 768.132 Millions	$ 29.048 Millions
Climb Bio Inc	25.98	$ 205.423 Millions	$ 7.906 Millions
Prothena Corporation Public Limited Company	23.73	$ 271.368 Millions	$ 11.434 Millions
Innoviva Inc	22.67	$ 1,134.297 Millions	$ 50.030 Millions
Kailera Therapeutics Inc	21.40	$ 901.454 Millions	$ 42.116 Millions
Cryoport inc	20.47	$ 653.343 Millions	$ 31.911 Millions
Roivant Sciences Ltd	20.30	$ 5,683.045 Millions	$ 279.911 Millions
Disc Medicine Inc	19.87	$ 682.816 Millions	$ 34.360 Millions
Mbx Biosciences Inc	19.14	$ 481.594 Millions	$ 25.167 Millions
Telomir Pharmaceuticals Inc	19.07	$ 4.516 Millions	$ 0.237 Millions
Onkure Therapeutics Inc	18.58	$ 163.305 Millions	$ 8.789 Millions
Siga Technologies Inc	17.27	$ 116.380 Millions	$ 6.738 Millions
Arrivent Biopharma inc	16.86	$ 393.691 Millions	$ 23.357 Millions
Keros Therapeutics Inc	16.36	$ 259.464 Millions	$ 15.858 Millions
Design Therapeutics Inc	16.36	$ 208.608 Millions	$ 12.753 Millions
Palvella Therapeutics Inc	15.85	$ 236.680 Millions	$ 14.928 Millions
Avalo Therapeutics Inc	15.63	$ 392.966 Millions	$ 25.135 Millions
Bioage Labs Inc	14.91	$ 283.637 Millions	$ 19.027 Millions
Damora Therapeutics Inc	14.72	$ 528.478 Millions	$ 35.892 Millions
Protagonist Therapeutics inc	14.42	$ 800.064 Millions	$ 55.464 Millions
Praxis Precision Medicines Inc	14.20	$ 745.323 Millions	$ 52.498 Millions

Date modified: 2026-11-07T09:09:35+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.